Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Pushkal Garg Sells 1,561 Shares

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) CMO Pushkal Garg sold 1,561 shares of Alnylam Pharmaceuticals stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $398,320.37. Following the transaction, the chief marketing officer now owns 13,537 shares in the company, valued at approximately $3,454,236.29. This trade represents a 10.34 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Pushkal Garg also recently made the following trade(s):

• On Tuesday, February 18th, Pushkal Garg sold 1,548 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $251.67, for a total value of $389,585.16.
• On Monday, January 27th, Pushkal Garg sold 52,592 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $285.00, for a total value of $14,988,720.00.
• On Thursday, December 12th, Pushkal Garg sold 1,752 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $251.00, for a total value of $439,752.00.
• On Tuesday, November 26th, Pushkal Garg sold 1,682 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $250.98, for a total value of $422,148.36.

Alnylam Pharmaceuticals Stock Down 0.2 %

NASDAQ ALNY traded down $0.41 during trading on Friday, hitting $250.59. 649,260 shares of the company traded hands, compared to its average volume of 693,578. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39. The business has a fifty day simple moving average of $254.04 and a 200 day simple moving average of $263.12. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The company has a market capitalization of $32.44 billion, a P/E ratio of -115.48 and a beta of 0.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). As a group, sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of institutional investors have recently made changes to their positions in ALNY. Regeneron Pharmaceuticals Inc. bought a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth about $1,045,822,000. Norges Bank bought a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth about $577,941,000. Capital Research Global Investors grew its position in Alnylam Pharmaceuticals by 32.9% during the fourth quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company's stock worth $1,639,767,000 after buying an additional 1,724,610 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its position in Alnylam Pharmaceuticals by 39.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company's stock worth $1,031,705,000 after buying an additional 1,245,195 shares in the last quarter. Finally, Marshall Wace LLP grew its position in Alnylam Pharmaceuticals by 496.6% during the fourth quarter. Marshall Wace LLP now owns 378,649 shares of the biopharmaceutical company's stock worth $89,100,000 after buying an additional 315,182 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on ALNY shares. Morgan Stanley raised their price objective on Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the stock an "equal weight" rating in a research note on Friday, February 14th. StockNews.com lowered Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, January 9th. Canaccord Genuity Group raised their target price on Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the stock a "buy" rating in a research report on Tuesday. Raymond James raised their target price on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an "outperform" rating in a research report on Friday, November 1st. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $320.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, February 14th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have given a buy rating to the company's stock. According to MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $299.48.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.